Physician profile
William Ryan Bailey
NPI 1598020836
$4,987.45
in general payments reported to CMS, 2019-2025
38 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.61 · 2020: $40.49 · 2021: $241 · 2022: $681 · 2023: $1,075 · 2024: $1,312 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,899.40 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,077.90 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novartis Pharmaceuticals Corporation | $536.51 | 2023-2025 | Leqvio |
| Astrazeneca Pharmaceuticals Lp | $349.07 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $325.14 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Supernus Pharmaceuticals, INC. | $220.64 | 2022-2024 | Qelbree |
| Astellas Pharma US INC | $215.79 | 2021-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $214.60 | 2023-2025 | |
| Lilly USA, LLC | $211.79 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Aimmune Therapeutics, INC. | $201.71 | 2024-2025 | Zenpep |
| Otsuka America Pharmaceutical, INC. | $164.47 | 2023-2025 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.86 | 2021-2025 | Jardiance |
| Abbott Laboratories | $130.31 | 2022-2024 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $106.61 | 2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.86 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $89.61 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.